Definitive Contract HHSN272201400052C

The University of California, San Diego was awarded a definitive cost-no-fee contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases totaling $12.7 million to support the Adjuvant Discovery Program. The prime contractor, UC San Diego, will work with several notable subcontractors including Inimmune Corp, Miltenyi Biotec, Repertoire Genesis, Life Technologies Corporation, Icahn School of Medicine at Mount Sinai, and Agilent Technologies over the...

This is a $9,807,060 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Chicago. The contract is for the Vaccine Adjuvant Discovery Program (VADP), which aims to evaluate and develop animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics. This contract is not set-aside and is a cost-type...

This federal contract award was issued by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) to Immport Therapeutics, Inc., doing business as Antigen Discovery Inc. The $110,458.00 firm fixed price purchase order is for ADI Leptospirosis work, with a performance period ending August 18, 2020. Antigen Discovery is a biotechnology company that provides microarray products and services to support the CDC's disease detection and response efforts, including...

This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...

This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS). The contract, valued at $196,994.14, is a delivery order for stability testing of CPG 7909, a vaccine adjuvant. The contract does not have a set-aside designation. ABL is a leading contract research and manufacturing organization that specializes in the development of gene...

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $4,148,210.00 Firm Fixed Price Definitive Contract to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, for the development of membrane-anchored cytokines as novel vaccine adjuvants for the elderly. This contract, which has a completion date of December 31, 2022, is part of the agency's "DEVELOPMENT OF MEMBRANE ANCHORED...

This federal contract award is for the PRODUCTION OF ADJUVANTS by Advanced Bioscience Laboratories, Inc. (ABL), a for-profit organization and manufacturer of goods. The contract, valued at $1,458,936.50, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type, with an ultimate completion...

This definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Celdara Medical of Lebanon, New Hampshire. With a value of $599,977, the firm fixed price contract supports research under Solicitation Number NIH-CDC-SBIR-2019 in adjuvant development for vaccines against infectious or immune-mediated diseases. Specifically, the prime contractor will conduct work requested under Topic 081 of the solicitation, which sought small...

This is a delivery order contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The purpose of this $8,609,815.00 firm-fixed-price contract modification is to fund Option Year 2 for the production of a CGMP (Current Good Manufacturing Practice) adjuvant at the clinical or commercial scale. The overall contract is part of the Pandemic...